Taiwan
· Delayed Price · Currency is TWD Medigen Biotechnology Company Description
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cytotherapy, advanced nucleic acid testing, generic drugs, aesthetic medicine, and vaccine-related products in Taiwan.
It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells.
It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States.
Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Shun-Lang Chang |
Contact Details
Address: No.3, Park Street Taipei, 11503 Taiwan | |
| Phone | 886 2 7736 1234 |
| Website | medigen.com.tw |
Stock Details
| Ticker Symbol | 3176 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0003176004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Shun-Lang Chang | General Manager |
| Ya-Ling Chiang | Assistant Vice President of Operations and Management Department |
| Chin-Yen Chen | Assistant Vice President of Drug Development Department |
| Feng-Hua Chen | Finance Manager and Accounting Officer |
| Chieh-Liang Lin | Chief Scientific Officer |